By: Eden Lorren Pabalan
CJC-1295 is a synthetic modification drug produced by ConjuChem, which contains D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. A more stable peptide is created from these substitutes and increases the half life of CJC-1295 from 7 minutes to 7 days. CJC-1295 was first formulated to be tested for curing visceral fat deposits in HIV patients.
ConjuChem is a peptide and drug developing company which uses DAC technology to continually formulate new legal drugs with more enhanced properties than original peptides.
Because of the longer half life of CJC-1295, it is plausible to use this peptide once per week with better results than GHRH. It is similar to compounds such as testosterone enanthate, Furthermore, scientific tests and researches performed in the Journal of Clinical Endocrinology & Metabolism has reported dose-dependent increases in mean plasma GH concentrations by 2-10 fold for more than 6 days and increased IGF-1 concentrations 1.5-3 fold for 9-11 days after a single injection.
One positive effect of CJC-1295 is its ability to induce slow wave sleep. Slow wave sleep is more popularly known as deep sleep and it helps in attaining the highest level of muscle growth and memory retention. SWS has declined tremendously in older adults and also with people who tend to exercise later in the evening. This peptide has a great benefit to side effect ratio that encompasses other drugs that are currently on the market. It would also be a good assistance to one’s training regimen or post cycle therapy.
This drug is proving to be promising to the market. Its synthetic substitutes are its advantage among other Growth Hormone products. Its primary objective which is to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss), is paving way for more experiments and positive results for better treatment in HIV.